- Conditions
- Chorioamnionitis, Intrapartum Fever, Intra-amniotic Infection
- Interventions
- Standard Antibiotic Treatment, No Antibiotic Treatment
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 634
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Preterm Labor, Preterm Birth
- Interventions
- Not listed
- Lead sponsor
- Ranjith Kamity, MD
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Prematurity, BPD - Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Newborn
- Interventions
- Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor, Tidal Volume Measurement using the Philips Respironics NM3 monitor
- Device
- Lead sponsor
- Baystate Medical Center
- Other
- Eligibility
- 5 Minutes to 60 Minutes
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Ureaplasma Infections
- Interventions
- Azithromycin, Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 2 Hours to 72 Hours
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Newark, Delaware • Baltimore, Maryland + 2 more
- Conditions
- Respiratory Distress Syndrome in Premature Infants, Very Low Birth Weight Baby
- Interventions
- iNO, Nitrogen
- Drug · Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 1 Minute to 2 Minutes
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Obstetric Labour, Premature
- Interventions
- GSK221149A, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 32
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more
- Conditions
- Premature Ovarian Failure
- Interventions
- DHEA
- Drug
- Lead sponsor
- Virginia Center for Reproductive Medicine
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Reston, Virginia
- Conditions
- Primary Ovarian Insufficiency, Premature Menopause
- Interventions
- A-PRP
- Procedure
- Lead sponsor
- Center for Human Reproduction
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dysfunction; Endocrine, Effects of Chemotherapy, Premature Ovarian Failure
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Infant Premature
- Interventions
- Higher Volume Feeding Goal
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Day to 1 Month
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Premature Birth, Absorption; Chemicals
- Interventions
- 17-Hydroxyprogesterone Capronate
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Tampa, Florida • St Louis, Missouri
- Conditions
- Preterm Infant, Development, Infant, Nutrition
- Interventions
- Prebiotic, Dextrose Control
- Dietary Supplement
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 7 Days to 10 Days
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Obstetric Labor, Premature, Venous Thrombosis
- Interventions
- Nifedipine
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Pregnancy, Premature Birth, Prenatal Care, Preterm Delivery, Preterm Birth
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 20,964 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Enterocolitis, Necrotizing, Premature Infant
- Interventions
- Bowel Ultrasound
- Diagnostic Test
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- Up to 28 Weeks
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Prematurity
- Interventions
- Human Milk Cream
- Dietary Supplement
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Days
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Houston, Texas • San Antonio, Texas
- Conditions
- Premature Birth of Newborn, Intestinal Malabsorption
- Interventions
- NTRA-2112, Placebo
- Drug
- Lead sponsor
- Elgan Pharma Ltd.
- Industry
- Eligibility
- 1 Day to 5 Days
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Greenville, North Carolina • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Intracranial Hemorrhages
- Interventions
- Phenobarbital, Saline
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Female only
- Enrollment
- 610 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1993 – 1997
- U.S. locations
- 11
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
- Conditions
- Preterm Infant Health, Premature Babies
- Interventions
- Human Milk Concentration Device, Standard of Care Fortified Feeding
- Device · Other
- Lead sponsor
- Mother's Milk is Best
- Industry
- Eligibility
- 32 Weeks to 35 Weeks
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Turner Syndrome, Ovarian Failure, Premature, Sex Chromosome Aberrations, Menopause, Perimenopause
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Transient Tachypnea of the Newborn
- Interventions
- Amount of total fluids
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- Up to 24 Hours
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Preterm Birth
- Interventions
- 17-Hydroxyprogesterone caproate 250mg or 500 mg., Safety study of 500 mg dose.
- Drug
- Lead sponsor
- Steve N. Caritis, MD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
- Conditions
- Menopause, Premature
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California